<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04134832</url>
  </required_header>
  <id_info>
    <org_study_id>7435</org_study_id>
    <nct_id>NCT04134832</nct_id>
  </id_info>
  <brief_title>Study of Pancreatic Neuroendocrine Tumors and Carcinomas in Alsace Region</brief_title>
  <official_title>Clinicopathological Assessment of Pancreatic Neuroendocrine Tumors and Carcinomas in Alsace Region</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Strasbourg, France</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Strasbourg, France</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Pancreatic Neuroendocrine tumors and carcinomas (pNET) see the last year their incidence and&#xD;
      prevalence going up. On the basis of their grade of differentiation and proliferation ratio&#xD;
      measured Ki67 staining, there are divided into 3 grade groups : Grade 1 with Ki67 between 1&#xD;
      and 3%, Grade 2 between 3 and 20% and well-differentiated neuroendocrine grade tumors 3 with&#xD;
      KI67 greater than 20%, so undifferentiated carcinomas.&#xD;
&#xD;
      pNET is a heterogenous group of tumors with variable prognosis. The aim of this study is to&#xD;
      identify the prognostic factors in this population, as well the place of&#xD;
      neutrophil-to-lymphocyte ratio as a prognostic marker. The primary endpoint is the&#xD;
      description of clinic and pathological parameters of patients from Alsace. The secondary&#xD;
      endpoints are the identification of prognostic factors in this population&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date type="Actual">June 27, 2019</start_date>
  <completion_date type="Anticipated">June 2020</completion_date>
  <primary_completion_date type="Anticipated">June 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>The survival will be evaluated by Kaplan Meier Method. The prognostic factors will be evaluated with univariate and multivariate analysis by Cox regression model.</measure>
    <time_frame>The participant will be followed-up for a maximum of 11 years, and 1 year at least.</time_frame>
  </primary_outcome>
  <enrollment type="Anticipated">250</enrollment>
  <condition>Pancreatic Neuroendocrine Tumor</condition>
  <eligibility>
    <study_pop>
      <textblock>
        Subject with histologically confirmed pancreatic neuroendocrine tumor or carcinoma, with&#xD;
        tumours or neuroendocrine carcinoma of the pancreas at any stage of the disease and covered&#xD;
        in one of the participating centres between 01/01/2008 and 01/01/2019&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion criteria:&#xD;
&#xD;
          1. Major topic ((≥18 years)&#xD;
&#xD;
          2. Subject with histologically confirmed pancreatic neuroendocrine tumor or carcinoma&#xD;
&#xD;
          3. Subject with tumours or neuroendocrine carcinoma of the pancreas at any stage of the&#xD;
             disease.&#xD;
&#xD;
          4. Subject covered in one of the participating centres between 01/01/2008 and 01/01/2019&#xD;
&#xD;
          5. Have a pre-therapeutic biological check-up&#xD;
&#xD;
          6. Subject who has not expressed opposition to the use of his or her data for research&#xD;
             purposes&#xD;
&#xD;
        Exclusion criteria:&#xD;
&#xD;
          1. Subject who expressed opposition to participate in the study&#xD;
&#xD;
          2. Lack of histological data&#xD;
&#xD;
          3. Minor subject&#xD;
&#xD;
          4. Patient under the protection of justice&#xD;
&#xD;
          5. Subject under guardianship or trusteeship&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Gabriel MALOUF, MD, PhD</last_name>
    <phone>33 3 88 11 62 22</phone>
    <email>gabriel.malouf@chru-strasbourg.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Service D'Hematologie Et D'Oncologie</name>
      <address>
        <city>Strasbourg</city>
        <zip>67098</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gabriel MALOUF, MD, PhD</last_name>
      <phone>33 3 88 11 62 22</phone>
      <email>gabriel.malouf@chru-strasbourg.fr</email>
    </contact>
    <investigator>
      <last_name>Gabriel MALOUF, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jean-Marc Limacher, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Emmanuel Achille</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Louis-Marie Dourthe</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Bernard Willemin</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Stéphanie Husson</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Meher Ben Abdelghani</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Véronique Debien</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>October 2019</verification_date>
  <study_first_submitted>October 18, 2019</study_first_submitted>
  <study_first_submitted_qc>October 18, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">October 22, 2019</study_first_posted>
  <last_update_submitted>October 18, 2019</last_update_submitted>
  <last_update_submitted_qc>October 18, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">October 22, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Pancreatic neuroendocrine tumors</keyword>
  <keyword>Neutrophil-to-lymphocyte ratio</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neuroendocrine Tumors</mesh_term>
    <mesh_term>Adenoma, Islet Cell</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

